Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays.

Polycomb repressive complex 2 (PRC2) acts as a primary writer for di- and tri-methylation of histone H3 at lysine 27. This protein plays an essential role in silencing gene expression. Enhancer of zeste 2 (EZH2), the catalytic subunit of PRC2, is considered as a promising therapeutic target for cancer. GSK126, a specific inhibitor of EZH2, is undergoing phase I trials for hypermethylation-related cancers. In addition, many derivatives of GSK126 are also commonly used in laboratory investigations. However, studies on the mechanism and drug development of EZH2 are limited by the absence of structural diversity of these inhibitors because they share similar SAM-like scaffolds. In this study, we generated a pharmacophore model based on reported EZH2 inhibitors and performed in silico screenings. Experimental validations led to the identification of two novel EZH2 inhibitors, DCE_42 and DCE_254, with IC50 values of 23 and 11μM, respectively. They also displayed significant anti-proliferation activity against lymphoma cell lines. Thus, we discovered potent EZH2 inhibitors with novel scaffold using combined in silico screening and experimental study. Results from this study can also guide further development of novel specific EZH2 inhibitors.

[1]  Hualiang Jiang,et al.  Identifying novel selective non-nucleoside DNA methyltransferase 1 inhibitors through docking-based virtual screening. , 2014, Journal of medicinal chemistry.

[2]  P. Atadja,et al.  Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation , 2012, Proceedings of the National Academy of Sciences.

[3]  E. Nestler,et al.  Epigenetic mechanisms in drug addiction. , 2008, Trends in molecular medicine.

[4]  H. Kubinyi.  QSAR and 3D QSAR in drug design Part 1: methodology , 1997 .

[5]  Diana C. Roe,et al.  BUILDER v.2: Improving the chemistry of a de novo design strategy , 1995, J. Comput. Aided Mol. Des..

[6]  M. Zheng,et al.  Interaction between DNA/histone methyltransferases and their inhibitors. , 2014, Current medicinal chemistry.

[7]  Jonathan B. Baell,et al.  Redox-active nuisance screening compounds and their classification , 2011 .

[8]  A. Melnick,et al.  The epigenetic basis of diffuse large B-cell lymphoma. , 2015, Seminars in hematology.

[9]  Sean Ekins,et al.  Pharmacophore-based discovery of ligands for drug transporters. , 2006, Advanced drug delivery reviews.

[10]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[11]  T. Jenuwein,et al.  The many faces of histone lysine methylation. , 2002, Current opinion in cell biology.

[12]  M. Beringer,et al.  Role of PRC2‐associated factors in stem cells and disease , 2015, The FEBS journal.

[13]  R. van Driel,et al.  Characterization of Interactions between the Mammalian Polycomb-Group Proteins Enx1/EZH2 and EED Suggests the Existence of Different Mammalian Polycomb-Group Protein Complexes , 1998, Molecular and Cellular Biology.

[14]  Tim J. Wigle,et al.  EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity , 2015, ACS medicinal chemistry letters.

[15]  Cheng Luo,et al.  Computational methods for drug design and discovery: focus on China , 2013, Trends in Pharmacological Sciences.

[16]  H. Kubinyi.  QSAR and 3D QSAR in drug design Part 2: applications and problems , 1997 .

[17]  Yi Zhang,et al.  SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. , 2004, Molecular cell.

[18]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2006, Nature.

[19]  Bruno Di Stefano,et al.  Polycomb complexes in stem cells and embryonic development , 2013, Development.

[20]  Wendy A. Warr,et al.  Scientific workflow systems: Pipeline Pilot and KNIME , 2012, Journal of Computer-Aided Molecular Design.

[21]  D. Reinberg,et al.  Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. , 2001, Genes & development.

[22]  J. Baell,et al.  Chemistry: Chemical con artists foil drug discovery , 2014, Nature.

[23]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[24]  Gisbert Schneider,et al.  Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.

[25]  R. Copeland,et al.  Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas , 2010, Proceedings of the National Academy of Sciences.

[26]  Tim J. Wigle,et al.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. , 2012, Nature chemical biology.

[27]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[28]  G. Hannon,et al.  Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells , 2009, Cell.

[29]  K. Hahn,et al.  An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. , 2013, ACS chemical biology.

[30]  B. Chait,et al.  Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement , 2003, Nature Immunology.

[31]  Hualiang Jiang,et al.  Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation. , 2012, Journal of medicinal chemistry.

[32]  Jiang Wu,et al.  Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy , 2008, Medicinal research reviews.

[33]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.